Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The phase 2 ACUITY trial met its primary safety endpoint ...
A deep-learning model trained on optical coherence tomography scans of the optic nerve head reliably distinguished among various types of optic nerve damage, such as glaucoma, non-arteritic anterior ...
Please provide your email address to receive an email when new articles are posted on . Being male or aged older than 40 years were consistently associated with poorer acute optic neuritis outcomes.
OCS-05 demonstrates safety and efficacy in treating acute optic neuritis, receiving FDA IND clearance for clinical development in the U.S. Small sample size of only 36 patients in the Phase 2 ACUITY ...
A research team led by the Department of Ophthalmology, School of Clinical Medicine, LKS Faculty of Medicine of The University of Hong Kong (HKUMed), with collaborators from the Faculty of Medicine of ...
ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ...
Comorbidities, especially cardiovascular and autoimmune diseases, were frequent in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD) and myelin oligodendrocyte ...
This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback